Table 2.
OGC discontinuation or reduction following belimumab initiation before and after IS use stratified by baseline SLE disease activity
| n (%) | Moderate baseline SLE | Severe baseline SLE | ||
|---|---|---|---|---|
| Patients initiating belimumab before IS use (N = 1909) |
Patients initiating belimumab after IS use (N = 3252) |
Patients initiating belimumab before IS use (N = 386) |
Patients initiating belimumab after IS use (N = 862) |
|
| Median (95% CI) time to OGC discontinuation or reduction to ADD < 5 mg in patients with OGC ADD ≥ 10 mg at index, months | 5.9 (4.7, 7.7) | 9.0 (7.1, 11.1) | 6.8 (4.6, 8.4) | 8.7 (6.6, 11.2) |
| Proportion of patients with cumulative incidence of OGC discontinuation or reduction of OGC ADD to < 5 mg in patients with OGC ADD ≥ 10 mg at index, n (%) | ||||
| 6 months | 83 (51.0) | 150 (40.9) | 43 (47.5) | 117 (42.2) |
| 12 months | 109 (69.9) | 206 (58.5) | 57 (64.9) | 155 (57.6) |
| 24 months | 128 (90.6) | 248 (76.2) | 66 (79.2) | 186 (75.2) |
Note: OGC dose = prednisone equivalent dose
ADD average daily dose, CI confidence interval, IS immunosuppressant, OGC oral glucocorticoid, SLE systemic lupus erythematosus